No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Ixico said on Tuesday that it expected revenue for the year ending 30 September to be ahead of market expectations at at least 8.0m, representing growth of about 22% on the prior year.
The AIM-traded neuroscience imaging and biomarker analytics specialist said the update replaced its previous forecast of 7.5m, which would have represented a 15% uplift.
Chief executive Bram Goorden said the stronger performance had been driven by "a continued uplift in contract wins, contract extensions, and revenue diversification," adding that it demonstrated "the fruits" of the strategy put in place in 2024.
At 0939 BST, shares in Ixico were up 15.69% at 9.4p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.